IMUGENE LIMITED - Announcements

0.00%

1.5¢

Market Cap $112.0M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Announcements

Filter Results

All Price Sensitive Only

IMU	Notification of cessation of securities - IMU		06/06/25	14.55KB	Share
IMU	1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial		02/06/25	167.47KB	Share
IMU	Dr John Byon appointed Chief Medical Officer		30/05/25	171.33KB	Share
IMU	Consolidation/Split - IMU		29/05/25	28.92KB	Share
IMU	Letter to Imugene Shareholders		28/05/25	147.82KB	Share
IMU	Addendum to Notice of Extraordinary General Meeting		27/05/25	169.23KB	Share
IMU	Notice of Extraordinary General Meeting/Proxy Form	PRICE SENSITIVE	27/05/25	209.01KB	Share
IMU	Notification regarding unquoted securities - IMU		23/05/25	20.79KB	Share
IMU	Notification of cessation of securities - IMU		21/05/25	17.32KB	Share
IMU	Proposed Consolidation of Capital		16/05/25	144.03KB	Share
IMU	Letter to Shareholders		01/05/25	179.62KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	629.98KB	Share
IMU	Application for quotation of securities - IMU		14/04/25	17.69KB	Share
IMU	Notification of cessation of securities - IMU		11/04/25	15.98KB	Share
IMU	Notification regarding unquoted securities - IMU		11/04/25	17.65KB	Share
IMU	Investor Update & FAQ Webinar		10/04/25	142.4KB	Share
IMU	1st dose level cleared IV combination arm onCARlytics trial		03/04/25	170.29KB	Share
IMU	Azer-cel Granted FDA Fast Track Designation in Blood Cancer	PRICE SENSITIVE	19/03/25	167.35KB	Share
IMU	Application for quotation of securities - IMU		13/03/25	18.09KB	Share
IMU	S&P DJI Announces March 2025 Quarterly Rebalance	PRICE SENSITIVE	07/03/25	174.42KB	Share
IMU	Darren Keamy Appointed CFO and Company Secretary		04/03/25	179.74KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	1.24MB	Share
IMU	Imugene Granted India Patent for Oncolytic Virotherapy CF33	PRICE SENSITIVE	27/02/25	148.12KB	Share
IMU	Imugene OnCARlytics Patent Allowance in China	PRICE SENSITIVE	26/02/25	139.63KB	Share
IMU	Change of Directors Interest Notice x 5		21/02/25	22.98KB	Share
IMU	Notification regarding unquoted securities - IMU		21/02/25	21.94KB	Share
IMU	Application for quotation of securities - IMU		21/02/25	18.3KB	Share
IMU	Azer-cel demonstrates two additional Complete Responses	PRICE SENSITIVE	14/02/25	284.4KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/25	422.97KB	Share
IMU	Notification of cessation of securities - IMU		29/01/25	14.56KB	Share
IMU	Application for quotation of securities - IMU		29/01/25	17.69KB	Share
IMU	Imugene Receives A$20 million for Convertible Notes Issuance	PRICE SENSITIVE	29/01/25	142.24KB	Share
IMU	Notification regarding unquoted securities - IMU		28/01/25	23.89KB	Share
IMU	Release of Shares from Voluntary Escrow		24/01/25	145.52KB	Share
IMU	Cleansing Notice		24/01/25	484.2KB	Share
IMU	Notification regarding unquoted securities - IMU		24/01/25	21.22KB	Share
IMU	Results of Meeting		22/01/25	154.16KB	Share
IMU	Imugene EGM Presentation		22/01/25	942.88KB	Share
IMU	Application for quotation of securities - IMU		10/01/25	23.72KB	Share
IMU	Imugene Receives $11.7m R&D Tax Refund	PRICE SENSITIVE	10/01/25	138KB	Share
IMU	First Australian Patient Dosed in Phase 1b azer-cel Trial	PRICE SENSITIVE	03/01/25	166.55KB	Share
IMU	Proposed issue of securities - IMU		24/12/24	20.62KB	Share
IMU	Notice of Extraordinary General Meeting/Proxy Form		23/12/24	463.88KB	Share
IMU	Issuance of Convertible Notes & Warrants for up to $46m	PRICE SENSITIVE	23/12/24	282.37KB	Share
IMU	Azer-cel Accepted for Presentation at ASTCT Tandem Meetings		20/12/24	145.54KB	Share
IMU	Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund	PRICE SENSITIVE	19/12/24	143.5KB	Share
IMU	Updated Appendix 3Z		20/11/24	160.7KB	Share
IMU	Final Director's Interest Notice		20/11/24	3.6KB	Share
IMU	Director Resignation		15/11/24	160.53KB	Share
IMU	Imugene 2024 AGM Results		14/11/24	181.49KB	Share
IMU	Imugene AGM Presentation		14/11/24	2.14MB	Share
IMU	onCARlytics Trial Doses First Patient in IT Combination Arm	PRICE SENSITIVE	11/11/24	189.72KB	Share
IMU	Imugene Opens First Australian Site for azer-cel Trial	PRICE SENSITIVE	08/11/24	214.26KB	Share
IMU	Complete Response in MAST Study Maintained Over Two Years	PRICE SENSITIVE	05/11/24	191.62KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	461.53KB	Share
IMU	Notification regarding unquoted securities - IMU		14/10/24	20.58KB	Share
IMU	Notification of cessation of securities - IMU		14/10/24	16.56KB	Share
IMU	Application for quotation of securities - IMU		14/10/24	17.62KB	Share
IMU	Notice of Annual General Meeting/Proxy Form		14/10/24	976.19KB	Share
IMU	Change of Director's Interest Notice - PH		30/09/24	256.6KB	Share
IMU	Imugene Receives Orphan Drug Designation for VAXINIA	PRICE SENSITIVE	18/09/24	237.05KB	Share
IMU	Appendix 2A		11/09/24	435.96KB	Share
IMU	Imugene Corporate Presentation		09/09/24	3.57MB	Share
IMU	Cleansing Notice		04/09/24	198.65KB	Share
IMU	Application for quotation of securities - IMU		04/09/24	17.67KB	Share
IMU	Imugene Azer-cel Webinar Presentation		04/09/24	1.37MB	Share
IMU	Imugene Webinar - Azer-cel Trial Update		03/09/24	211.74KB	Share
IMU	Three Complete Responses in Azer-Cel Phase 1b Trial	PRICE SENSITIVE	02/09/24	319.48KB	Share
IMU	Imugene ESG Report 2024		30/08/24	2.77MB	Share
IMU	Corporate Governance Statement 2024 and Appendix 4G		30/08/24	671.7KB	Share
IMU	Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/24	5.58MB	Share
IMU	Release of Shares from Voluntary Escrow		02/08/24	130.28KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	458.91KB	Share
IMU	Notification of cessation of securities - IMU		12/07/24	16.85KB	Share
IMU	Notification regarding unquoted securities - IMU		12/07/24	19.49KB	Share
IMU	First patient dosed in Phase 1 bile tract cancer trial	PRICE SENSITIVE	10/07/24	368.53KB	Share
IMU	Change of Director's Interest Notice x6		08/07/24	49.1KB	Share
IMU	Application for quotation of securities - IMU		08/07/24	22.16KB	Share
IMU	Imugene Corporate Presentation		04/07/24	2.06MB	Share
IMU	Imugene onCARlytics Doses First Patient in IV Combination	PRICE SENSITIVE	24/06/24	169.93KB	Share
IMU	Imugene Presentation to Bell Potter Conference		30/05/24	1.76MB	Share
IMU	Application for quotation of securities - IMU		06/05/24	17.43KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	484.57KB	Share
IMU	Change of Director's Interest Notice - PH		23/04/24	4.96KB	Share
IMU	Notification regarding unquoted securities - IMU		19/04/24	20.68KB	Share
IMU	Imugene & Kincell Bio Strategic Partnership Investor Webinar		17/04/24	138.92KB	Share
IMU	Imugene and Kincell Bio Announce Strategic Partnership	PRICE SENSITIVE	16/04/24	220.02KB	Share
IMU	Notification of cessation of securities - IMU		15/04/24	14.65KB	Share
IMU	Notification regarding unquoted securities - IMU		15/04/24	17.53KB	Share
IMU	Bile Tract Cancer Study Opens after MAST High Dose Clearance	PRICE SENSITIVE	15/04/24	217.25KB	Share
IMU	VAXINIA and HER-Vaxx featured at the AACR Annual Meeting	PRICE SENSITIVE	08/04/24	173.17KB	Share
IMU	Oncolytic Virotherapy CF33 Patent Granted in China	PRICE SENSITIVE	04/04/24	163.48KB	Share
IMU	Imugene to present at 2024 Cholangiocarcinoma Conference	PRICE SENSITIVE	03/04/24	161.29KB	Share
IMU	Cleansing Notice		02/04/24	141.2KB	Share
IMU	Application for quotation of securities - IMU		02/04/24	20.1KB	Share
IMU	Phase 1 onCARlytics Trial Advances to Combination Arm	PRICE SENSITIVE	11/03/24	193.84KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	1.15MB	Share
IMU	Phase 1 onCARlytics Trial Doses First Intravenous Patient	PRICE SENSITIVE	15/02/24	192.99KB	Share
IMU	Notice of change of interests of substantial holder - PH		02/02/24	179.34KB	Share
IMU	Change of Director's Interest Notice - PH		01/02/24	5.05KB	Share

IMU Notification of cessation of securities - IMU
06/06/25		14.55KB	Share
IMU 1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial
02/06/25		167.47KB	Share
IMU Dr John Byon appointed Chief Medical Officer
30/05/25		171.33KB	Share
IMU Consolidation/Split - IMU
29/05/25		28.92KB	Share
IMU Letter to Imugene Shareholders
28/05/25		147.82KB	Share
IMU Addendum to Notice of Extraordinary General Meeting
27/05/25		169.23KB	Share
IMU Notice of Extraordinary General Meeting/Proxy Form
27/05/25	PRICE SENSITIVE	209.01KB	Share
IMU Notification regarding unquoted securities - IMU
23/05/25		20.79KB	Share
IMU Notification of cessation of securities - IMU
21/05/25		17.32KB	Share
IMU Proposed Consolidation of Capital
16/05/25		144.03KB	Share
IMU Letter to Shareholders
01/05/25		179.62KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	629.98KB	Share
IMU Application for quotation of securities - IMU
14/04/25		17.69KB	Share
IMU Notification of cessation of securities - IMU
11/04/25		15.98KB	Share
IMU Notification regarding unquoted securities - IMU
11/04/25		17.65KB	Share
IMU Investor Update & FAQ Webinar
10/04/25		142.4KB	Share
IMU 1st dose level cleared IV combination arm onCARlytics trial
03/04/25		170.29KB	Share
IMU Azer-cel Granted FDA Fast Track Designation in Blood Cancer
19/03/25	PRICE SENSITIVE	167.35KB	Share
IMU Application for quotation of securities - IMU
13/03/25		18.09KB	Share
IMU S&P DJI Announces March 2025 Quarterly Rebalance
07/03/25	PRICE SENSITIVE	174.42KB	Share
IMU Darren Keamy Appointed CFO and Company Secretary
04/03/25		179.74KB	Share
IMU Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	1.24MB	Share
IMU Imugene Granted India Patent for Oncolytic Virotherapy CF33
27/02/25	PRICE SENSITIVE	148.12KB	Share
IMU Imugene OnCARlytics Patent Allowance in China
26/02/25	PRICE SENSITIVE	139.63KB	Share
IMU Change of Directors Interest Notice x 5
21/02/25		22.98KB	Share
IMU Notification regarding unquoted securities - IMU
21/02/25		21.94KB	Share
IMU Application for quotation of securities - IMU
21/02/25		18.3KB	Share
IMU Azer-cel demonstrates two additional Complete Responses
14/02/25	PRICE SENSITIVE	284.4KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/01/25	PRICE SENSITIVE	422.97KB	Share
IMU Notification of cessation of securities - IMU
29/01/25		14.56KB	Share
IMU Application for quotation of securities - IMU
29/01/25		17.69KB	Share
IMU Imugene Receives A$20 million for Convertible Notes Issuance
29/01/25	PRICE SENSITIVE	142.24KB	Share
IMU Notification regarding unquoted securities - IMU
28/01/25		23.89KB	Share
IMU Release of Shares from Voluntary Escrow
24/01/25		145.52KB	Share
IMU Cleansing Notice
24/01/25		484.2KB	Share
IMU Notification regarding unquoted securities - IMU
24/01/25		21.22KB	Share
IMU Results of Meeting
22/01/25		154.16KB	Share
IMU Imugene EGM Presentation
22/01/25		942.88KB	Share
IMU Application for quotation of securities - IMU
10/01/25		23.72KB	Share
IMU Imugene Receives $11.7m R&D Tax Refund
10/01/25	PRICE SENSITIVE	138KB	Share
IMU First Australian Patient Dosed in Phase 1b azer-cel Trial
03/01/25	PRICE SENSITIVE	166.55KB	Share
IMU Proposed issue of securities - IMU
24/12/24		20.62KB	Share
IMU Notice of Extraordinary General Meeting/Proxy Form
23/12/24		463.88KB	Share
IMU Issuance of Convertible Notes & Warrants for up to $46m
23/12/24	PRICE SENSITIVE	282.37KB	Share
IMU Azer-cel Accepted for Presentation at ASTCT Tandem Meetings
20/12/24		145.54KB	Share
IMU Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
19/12/24	PRICE SENSITIVE	143.5KB	Share
IMU Updated Appendix 3Z
20/11/24		160.7KB	Share
IMU Final Director's Interest Notice
20/11/24		3.6KB	Share
IMU Director Resignation
15/11/24		160.53KB	Share
IMU Imugene 2024 AGM Results
14/11/24		181.49KB	Share
IMU Imugene AGM Presentation
14/11/24		2.14MB	Share
IMU onCARlytics Trial Doses First Patient in IT Combination Arm
11/11/24	PRICE SENSITIVE	189.72KB	Share
IMU Imugene Opens First Australian Site for azer-cel Trial
08/11/24	PRICE SENSITIVE	214.26KB	Share
IMU Complete Response in MAST Study Maintained Over Two Years
05/11/24	PRICE SENSITIVE	191.62KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	461.53KB	Share
IMU Notification regarding unquoted securities - IMU
14/10/24		20.58KB	Share
IMU Notification of cessation of securities - IMU
14/10/24		16.56KB	Share
IMU Application for quotation of securities - IMU
14/10/24		17.62KB	Share
IMU Notice of Annual General Meeting/Proxy Form
14/10/24		976.19KB	Share
IMU Change of Director's Interest Notice - PH
30/09/24		256.6KB	Share
IMU Imugene Receives Orphan Drug Designation for VAXINIA
18/09/24	PRICE SENSITIVE	237.05KB	Share
IMU Appendix 2A
11/09/24		435.96KB	Share
IMU Imugene Corporate Presentation
09/09/24		3.57MB	Share
IMU Cleansing Notice
04/09/24		198.65KB	Share
IMU Application for quotation of securities - IMU
04/09/24		17.67KB	Share
IMU Imugene Azer-cel Webinar Presentation
04/09/24		1.37MB	Share
IMU Imugene Webinar - Azer-cel Trial Update
03/09/24		211.74KB	Share
IMU Three Complete Responses in Azer-Cel Phase 1b Trial
02/09/24	PRICE SENSITIVE	319.48KB	Share
IMU Imugene ESG Report 2024
30/08/24		2.77MB	Share
IMU Corporate Governance Statement 2024 and Appendix 4G
30/08/24		671.7KB	Share
IMU Appendix 4E and Annual Report
30/08/24	PRICE SENSITIVE	5.58MB	Share
IMU Release of Shares from Voluntary Escrow
02/08/24		130.28KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	458.91KB	Share
IMU Notification of cessation of securities - IMU
12/07/24		16.85KB	Share
IMU Notification regarding unquoted securities - IMU
12/07/24		19.49KB	Share
IMU First patient dosed in Phase 1 bile tract cancer trial
10/07/24	PRICE SENSITIVE	368.53KB	Share
IMU Change of Director's Interest Notice x6
08/07/24		49.1KB	Share
IMU Application for quotation of securities - IMU
08/07/24		22.16KB	Share
IMU Imugene Corporate Presentation
04/07/24		2.06MB	Share
IMU Imugene onCARlytics Doses First Patient in IV Combination
24/06/24	PRICE SENSITIVE	169.93KB	Share
IMU Imugene Presentation to Bell Potter Conference
30/05/24		1.76MB	Share
IMU Application for quotation of securities - IMU
06/05/24		17.43KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	484.57KB	Share
IMU Change of Director's Interest Notice - PH
23/04/24		4.96KB	Share
IMU Notification regarding unquoted securities - IMU
19/04/24		20.68KB	Share
IMU Imugene & Kincell Bio Strategic Partnership Investor Webinar
17/04/24		138.92KB	Share
IMU Imugene and Kincell Bio Announce Strategic Partnership
16/04/24	PRICE SENSITIVE	220.02KB	Share
IMU Notification of cessation of securities - IMU
15/04/24		14.65KB	Share
IMU Notification regarding unquoted securities - IMU
15/04/24		17.53KB	Share
IMU Bile Tract Cancer Study Opens after MAST High Dose Clearance
15/04/24	PRICE SENSITIVE	217.25KB	Share
IMU VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
08/04/24	PRICE SENSITIVE	173.17KB	Share
IMU Oncolytic Virotherapy CF33 Patent Granted in China
04/04/24	PRICE SENSITIVE	163.48KB	Share
IMU Imugene to present at 2024 Cholangiocarcinoma Conference
03/04/24	PRICE SENSITIVE	161.29KB	Share
IMU Cleansing Notice
02/04/24		141.2KB	Share
IMU Application for quotation of securities - IMU
02/04/24		20.1KB	Share
IMU Phase 1 onCARlytics Trial Advances to Combination Arm
11/03/24	PRICE SENSITIVE	193.84KB	Share
IMU Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	1.15MB	Share
IMU Phase 1 onCARlytics Trial Doses First Intravenous Patient
15/02/24	PRICE SENSITIVE	192.99KB	Share
IMU Notice of change of interests of substantial holder - PH
02/02/24		179.34KB	Share
IMU Change of Director's Interest Notice - PH
01/02/24		5.05KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $112.0M

Open	High	Low	Value	Volume
1.5¢	1.6¢	1.4¢	$125.4K	8.369M

Buyers (Bids)

No.	Vol.	Price($)
76	17029463	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	1061875	3

View Market Depth

No.	Vol.	Price($)
67	15122749	0.014
35	10959455	0.013
40	8162244	0.012
13	3263001	0.011
30	6569728	0.010

Price($)	Vol.	No.
0.015	873992	2
0.016	10695661	30
0.017	6170154	16
0.018	6533023	29
0.019	6839697	18

Last trade - 16.10pm 13/06/2025 (20 minute delay)

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories